Abeona Therapeutics Collaborates with Beacon Therapeutics to Develop AAV204 Capsid for Certain Ophthalmology Indications
Shots:
- Abeona & Beacon have entered into a non-exclusive agreement under which Beacon will assess the company’s AAV204 capsid for 12mos. to develop & commercialize gene therapies for eye diseases
- Beacon gets an option of a global, non-exclusive license to use AAV204 with up to five targets & rights to use AAV204 with 4 other nominated targets, under certain conditions. It will develop & commercialize all licensed candidates
- Abeona will get an upfront if Beacon exercises the option, development, regulatory & sales milestones plus global net-sales-based tiered royalties. The licensed targets will be different from those currently being developed by Abeona
Ref: Abeona Therapeutics | Image: Abeona Therapeutics & Beacon Therapeutics
Related News: Ultragenyx Entered into an Exclusive License Agreement with Abeona for ABO-102 (UX111) to Treat Sanfilippo Syndrome Type A
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
